{"analyses":[{"ciLowerLimit":"14.1","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"328","groupDescription":"BNP pg/mL, baseline versus end study values","groupIds":["OG000"],"nonInferiorityComment":"P-values and confidence intervals are not adjusted for multiple testing","nonInferiorityType":"OTHER","pValue":"0.035","paramType":"Mean outcome change","paramValue":"171","statisticalComment":"degrees of freedom = 12","statisticalMethod":"Mixed Models Analysis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"703","value":"883"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Cardiac biomarkers (BNP, Troponin I) were assessed at baseline, 6 and 12 months, with change at end of study reported","dispersionType":"Standard Deviation","groups":[{"description":"Patients with predominant amyloid involvement of the heart.","id":"OG000","title":"Cardiomyopathy"}],"paramType":"MEAN","populationDescription":"Analysis is limited to the patients with predominant amyloid heart involvement at enrollment. Mixed models analyses of change from baseline levels of cardiac biomarkers (BNP, Troponin I) were performed to include all collected data.","reportingStatus":"POSTED","timeFrame":"12 months","title":"Amyloid Cardiomyopathy: BNP","type":"PRIMARY","unitOfMeasure":"pg/mL"}